VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Checkpoint inhibitors and their potential role in MM

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential role of checkpoint inhibitors in the myeloma treatment landscape. Although these agents are not recommended for standard of care (SOC) treatment, Dr Usmani highlights the possibility of exploring combination approaches with checkpoint inhibition in future clinical trials. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter